Cargando…
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing
Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal disorder caused by deficiency of iduronate 2-sulfatase (IDS), leading to accumulation of glycosaminoglycans (GAGs) in tissues of affected individuals, progressive disease, and shortened lifespan. Currently available enzyme rep...
Autores principales: | Laoharawee, Kanut, DeKelver, Russell C., Podetz-Pedersen, Kelly M., Rohde, Michelle, Sproul, Scott, Nguyen, Hoang-Oanh, Nguyen, Tam, St. Martin, Susan J., Ou, Li, Tom, Susan, Radeke, Robert, Meyer, Kathleen E., Holmes, Michael C., Whitley, Chester B., Wechsler, Thomas, McIvor, R. Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080131/ https://www.ncbi.nlm.nih.gov/pubmed/29580682 http://dx.doi.org/10.1016/j.ymthe.2018.03.002 |
Ejemplares similares
-
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome
por: Ou, Li, et al.
Publicado: (2019) -
Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome
por: Laoharawee, Kanut, et al.
Publicado: (2023) -
ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice
por: Pagant, Silvere, et al.
Publicado: (2021) -
Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021) -
Increased Longevity and Metabolic Correction Following Syngeneic Bone Marrow Transplantation in a Murine Model of Mucopolysaccharidosis Type I
por: Wolf, Daniel A., et al.
Publicado: (2011)